The 16 references without contexts in paper T. Voznesenskaya G., Т. Вознесенская Г. (2015) “СИНДРОМ АПАТИИ // APATHY SYNDROME” / spz:neicon:nevro:y:2013:i:3:p:4-10

12
Alexopoulos G.S., Bruce M.L., Silbersweig D. et al. Vascular depression: a new view of late-onset depression. Dialog. Clin. Neurosci. Depress. Elderly. 1999; 1 (2): 68—80.
(check this in PDF content)
13
Alexopoulos G.S. Depression in the elderly. Lancet. 2005; 365: 1961—70.
(check this in PDF content)
15
Fuh J.L., Wang S.J., Cummings J.L. Neuropsychiatric profi les in patients with Alzheimer disease and vascular dementia. J. Neurol. Neurosurg. Psychiatry. 2005; 76 (10): 1337—41.
(check this in PDF content)
16
Starkstein S.E., Fedoroff J.P., Price T.R. et al Apathy following cerebrovascular lesions. Stroke. 1993; 24: 1625—30.
(check this in PDF content)
54
Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс; 2010.
(check this in PDF content)
55
Федорова Н.В., Никитина А.В. Прамипексол в корекции аффективных нарушений при болезни Паркинсона. Консилиум Медикум. Неврология и ревматология. 2012; 1: 74—9.
(check this in PDF content)
56
Cummings J.L., Mackell J., Kaufer D. Behavioral effects of current Alzheimer’s disease treatments: a descriptive review. Alzheimers Dement. 2008; 4 (1): 49—60.
(check this in PDF content)
57
Daly E.J., Falk W.E., Brown P. Cholinesterase inhibitors for behavioral disturbance in dementia. Cur. Psychiatr. Rep. 2001; 3: 251—8.
(check this in PDF content)
58
Feldman H., Gauthier S., Hecker J., Vellas B. et al. A 24-week, randomised, doubl blind study of donepezil in moderate to severe Alzheimer disease. Neurology. 2001; 57: 613—20.
(check this in PDF content)
59
Francis P.T. Glutamatergic approaches to the treatment of cognitive and behavioural symptoms in Alzheimer disease. Neurodegenerat. Dis. 2008; 5 (3—4): 241—3.
(check this in PDF content)
60
Gauthier S., Feldman H., Hecker J. et al. Effi cacy of donepezil on behavioral symptoms in patient with moderete to severe AD. Int. Psychogeriatr. 2002; 14: 389—404.
(check this in PDF content)
61
Gauthier S., Wirth Y., Mobius H.J. Effects of memantine on behavioural symptoms in Alzheimer disease patients — an analysis of the NPI data of two randomized controlled studies. Int. J. Geriatr. Psychiatry. 2005; 20 (5): 459—64.
(check this in PDF content)
62
Gauthier S., Loft H., Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer disease by memantine — a pooled data analysis. Int. J. Geriatr. Psychiatry. 2008; 23 (5): 537—45.
(check this in PDF content)
63
Gauthier S., Cooper, Loft H. Specifi c benefi ts of memantine on behavioural symptoms in patients with moderate to severe AD. Poster J. Alzcheimer Dementia. 2006; 2 (3, Suppl.): S370.
(check this in PDF content)
64
Loy C., Schneider L. Galantamine for Alzheimer disease and MCI. Cochrane Database Syst. Rev. 2006; 1: CD001747.
(check this in PDF content)
65
Tariot P.N., Farlow M.R., Grosberg G.T., Gracham S.M. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receving donepezil: a randomized controlled trial. J.A.M.A. 2004; 291: 317—24.
(check this in PDF content)